Using PET-MRI imaging for esophagogastric cancer treatment
Feasibility Study of PET-MRI as a Platform for Image Guidance and Adaptive Radiation Therapy in Patients With Esophagogastric Cancer
NA · University Health Network, Toronto · NCT05796102
This study is testing whether using PET-MRI imaging during radiation treatment can improve care for patients with esophagogastric cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Health Network, Toronto (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05796102 on ClinicalTrials.gov |
What this trial studies
This study investigates the feasibility of incorporating PET-MRI imaging into the radiation treatment workflow for patients with esophagogastric cancer. It involves a single-arm approach where imaging is performed before, during, and after radiation treatment. The goal is to gather data that could enhance future radiation therapy planning and patient care. The study will include up to 15 patients and is conducted at a single center.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with locally advanced esophageal cancer who are eligible for conventional radiation therapy.
Not a fit: Patients with contraindications for MRI or gadolinium, those who are pregnant or breastfeeding, or individuals with pacemakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the integration of advanced imaging techniques into radiation therapy for better treatment outcomes in esophagogastric cancer patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in utilizing advanced imaging techniques in cancer treatment workflows.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18 years or older * Diagnosed with locally advanced esophageal cancer being considered for conventional RT \>4 weeks * Ability and willingness to provide written informed consent Exclusion Criteria: * Contraindication for MRI * Contraindication for Gadolinium (i.e. inability to lie supine for at least 60 minutes) * Any patient who is pregnant or breastfeeding * Pacemaker or implanted defibrillator * Claustrophobia
Where this trial is running
Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: Rebecca K S Wong, MD
- Email: rebecca.wong@uhn.ca
- Phone: 4169462000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Esophagogastric Cancer